LOS ANGELES - s4story -- CellxLife, a Los Angeles-based biotechnology company focused on next-generation immunotherapies, is advancing a new generation of therapeutic cancer vaccines designed to help the body's own immune system recognize, attack, and remember cancer cells. CellxLife is currently advancing two Phase II trials in ovarian cancer and will soon be entering a Phase II trial in pediatric cancer. Both programs are based on platform technologies that may be applicable across multiple cancer indications.

Unlike traditional vaccines that prevent infectious diseases, therapeutic cancer vaccines are designed for people already diagnosed with cancer. Their goal is to educate the immune system to identify cancer cells, eliminate them, and develop long-lasting immune memory that may help reduce the risk of the disease returning.

Recent scientific advances have demonstrated that durable immune memory is becoming one of the most promising frontiers in cancer treatment. Researchers are developing vaccines designed to generate long-lasting immune responses that may continue protecting patients after initial treatment, offering new hope across multiple cancer types.

More on S For Story

• Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
• G.D. Griffiths Releases New Children's Picture Book - The Foopy Song
• Sounds of LA County: 27 Parks.108 Concerts. One County
• Casa Carlini acquires exclusive rights to historian Alan Strauss-Schom for its Storia imprint
• Only One Flight Stands Between Los Angeles Youth Leaders and a Life-Saving Mission in South Africa

These advances are reshaping how scientists think about treating cancer, not simply by removing tumors, but by empowering the immune system to provide ongoing surveillance against recurrence.

CellxLife is helping bring these innovative, non-toxic immunotherapies closer to patients. The company's technology is designed to activate a patient's own immune defenses, creating targeted immune responses while supporting long-term protection through immune memory.

"Our vision is to transform cancer treatment by helping the immune system do what it was designed to do: recognize cancer, fight it, and remember it," said Dr. Eric von Hofe, Co-Founder and Chief Executive Officer of CellxLife. "We believe therapeutic cancer vaccines represent one of the most important advances in oncology and have the potential to improve the lives of patients around the world."

CellxLife's leadership believes therapeutic vaccines may represent a significant shift toward more personalized, targeted, and patient-friendly cancer care by working with the body's natural biology rather than relying on broadly toxic approaches.

More on S For Story

• Participant in Frankfort Book Fair 2026
• Stigma Across Borders: Concerns Grow Over Discrimination Against Shincheonji Members Abroad
• World Cup Crowds Are a Stress Test for America's Restrooms
• Postmortem Pathology Expands Access to Private Autopsy Services in Las Vegas
• How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure

"CellxLife was founded with the belief that patients deserve safer, smarter options," said Ruvin Orbach, Founder of CellxLife. "We are committed to bringing innovative cancer immunotherapies to patients and helping lead the next generation of medicine that focuses on the power of the immune system."

About CellxLife (http://cellxlife.com)

CellxLife is a Los Angeles, California-based biotechnology company developing next-generation, non-toxic cancer immunotherapies designed to harness the body's own immune system to recognize, target, and remember cancer. The Company's mission is to develop innovative therapeutic vaccines and immune-based treatments that may improve long-term outcomes for patients while helping redefine the future of cancer care. For more information about CellxLife, visit the company's website.